

**Cancer Care 2015-2017
Standing Committee Meeting
May 18-19, 2016**

National Quality Forum
Executive Building
1030 15th Street, NW
9th Floor Conference Center
Washington, DC 20005
(202) 783-1300

Please use the following information to access the conference call line and webinar:

Day 1:

Public dial-in number: 877-303-9138

Webinar Link: <http://nqf.commpartners.com>

Webinar Meeting ID Day 1: 355627

Day 2:

Public dial-in number: 877-303-9138

Webinar Link: <http://nqf.commpartners.com>

Webinar Meeting ID Day 2: 885756

AGENDA

Day 1: May 18, 2016

8:30am **Continental Breakfast**

9:00am **Welcome**

David Cella, PhD, Co-Chair

Karen Fields, MD, Co-Chair

Melissa Mariñelarena, RN, MPA, Senior Director

9:10am **Introductions and Disclosure of Interest**

Marcia Wilson, PhD, Senior Vice President

9:20am **Project Introduction and Overview of Evaluation Process**

Shaonna Gorham, MS, PMP, Senior Project Manager

- 9:45am **Overview of Maintenance Measure Review**
Amber Sterling, MPH, Project Manager
- 9:55am **Discussion on eMeasures – Legacy Measures**
Jason Goldwater, MA, MPA, Senior Director
- 10:05am **Consideration of Maintenance Candidate Measures (Thoracic)**
- #0459: Risk-Adjusted Morbidity: Length of Stay >14 Days After Elective Lobectomy for Lung Cancer (Society of Thoracic Surgeons)
 - #0460: Risk-Adjusted Morbidity and Mortality for Esophagectomy for Cancer (Society of Thoracic Surgeons)
- 11:30am **Break**
- 11:45am **Consideration of Maintenance Candidate Measures (Breast)**
- #0508: Diagnostic Imaging: Inappropriate Use of “Probably Benign” Assessment Category in Screening Mammograms (American College of Radiology)
 - #0509: Diagnostic Imaging: Reminder System for Screening Mammograms (American College of Radiology)
- 12:30pm **NQF Member and Public Comment**
- 12:45pm **Lunch**
- 1:15pm **Consideration of Maintenance Candidate Measures (Breast)**
- #0219: Post breast conservation surgery irradiation (American College of Surgeons)
 - #0220: Adjuvant hormonal therapy (American College of Surgeons)
 - #0559: Combination chemotherapy is considered or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer (American College of Surgeons)
- 2:25pm **Consideration of Maintenance Candidate Measures (Colon & Prostate)**
- #0223: Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer (American College of Surgeons)
 - #0225: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (American College of Surgeons)

- 3:00pm **Break**
- 3:15pm **Consideration of Maintenance Candidate Measures (Colon & Prostate)**
- #0390: Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients (American Urological Association)
 - #0389: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (AMA/PCPI)
 - #2963: Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (AMA/PCPI) – *Legacy eMeasure*
- 4:30pm **NQF Member and Public Comment**
- 5:00 pm **Adjourn**

Day 2: May 19, 2016

- 8:30am **Continental Breakfast**
- 9:00am **Welcome, Recap of Day 1**
David Cella, PhD, Co-Chair
Karen Fields, MD, Co-Chair
- 9:15am **Consideration of Maintenance Candidate Measures (Hematology)**
- #0377: Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow (American Society of Hematology)
 - #0378: Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy (American Society of Hematology)
- 10:00am **Consideration of Maintenance Candidate Measures (Breast)**
- #1857: HER2 negative or undocumented breast cancer patients spared treatment with HER2-targeted therapies (American Society of Clinical Oncology)
 - #1878: HER2 testing for overexpression or gene amplification in patients with breast cancer (American Society of Clinical Oncology)
- 10:45am **Break**
- 11:00am **Consideration of New Measures**
- #2936: Admissions & Emergency (ED) Visits for Patients Receiving Outpatient Chemotherapy (Centers of Medicaid/Medicare)

11:45pm	NQF Member and Public Comment
12:00pm	Lunch
12:30pm	Consideration of New Measures <ul style="list-style-type: none"> • #2930: Febrile Neutropenia Risk Assessment Prior to Chemotherapy (RAND)
1:00pm	Additional Discussion Topics –Gaps within Episodes of Care
2:15pm	NQF Member and Public Comment
2:30pm	Next Steps/Committee Timeline <i>Kaitlynn Robinson-Ector, MPH, Project Analyst</i>
2:45pm	Adjourn